The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces increasing concerns about monopolies. A few dominant players control a significant percentage of the market, potentially limiting competition and driving up prices for consumers. This concern raises doubts about the long-term impact on patient access to af